MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to announce it has completed the first phase of its series of studies with the University of Melbourne to determine the cause and possible cure for hallucinogen-persisting perception disorder (HPPD). On July 2…

Source

Previous articleSilo Pharma Announces Expansion of Intellectual Property Portfolio
Next articleReunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET